ES01.01 Chemotherapy Is Strictly Additive To Immunotherapy

The document discussed the combination of chemotherapy and immune checkpoint inhibition (ICI) in treating advanced non-small cell lung cancer (NSCLC). It concluded that the interaction between chemotherapy and ICI was additive rather than synergistic, as evidenced by similar adverse event profiles in trials comparing chemo+ICI to chemo+placebo. Notably, immune-related adverse events were slightly higher in the chemo+ICI group. Despite chemotherapy's historical reputation as immunosuppressive, recent trials showed improved response rates, progression-free survival, and overall survival with the combination therapy. However, there was no definitive evidence favoring concurrent over sequential administration of chemo+ICI, and further research was needed to determine the optimal strategy.